NCT02957656View on ClinicalTrials.gov

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 30, 2018

Conditions

Influenza A Virus, H7N9 Subtype

Interventions

BIOLOGICAL

H7N9 pLAIV

10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device

BIOLOGICAL

H7N9 pIIV

Administered by intramuscular injection in the deltoid.

BIOLOGICAL

AS03 adjuvant

Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02957656 - Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant | Biotech Hunter | Biotech Hunter